Skip to content
ATLAS PREP HQ
Longevity

Prostamax

Lys-Glu-Asp-Pro (KEDP) tetrapeptide bioregulator

Peptide bioregulator research focused on prostate-tissue function and age-related changes.

Preclinical Evidence

Route

Intramuscular in the community page and referenced preclinical work.

Common format

20 mg vial

Research focus

prostate inflammation

Evidence level

Preclinical Evidence

Typical cycle

8–12 weeks

Longevity research motifLongevity

Prostamax in 30 seconds

Atlas Fast Read

What it is

Lys-Glu-Asp-Pro (KEDP) tetrapeptide bioregulator

Why people care

Peptide bioregulator research focused on prostate-tissue function and age-related changes.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

Prostamax is scientifically interesting for prostate inflammation, BPH models, but the current case is driven mainly by cell and animal data.

Overview

What is Prostamax?

Prostamax is lys-Glu-Asp-Pro (KEDP) tetrapeptide bioregulator. Peptide bioregulator research focused on prostate-tissue function and age-related changes.

Prostamax was developed within the Khavinson tissue-specific peptide-bioregulator program. Published studies focus mainly on preclinical prostate inflammation, chromatin effects, and tissue regulation.

Mechanism

How it works

KEDP is proposed to alter chromatin/gene regulation in prostate-related tissues. Rat models report reduced inflammatory and fibrotic changes in prostatitis-like conditions.

Research areas

prostate inflammationBPH modelschromatin regulationprostate tissue aging

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No strong controlled human evidence establishes Prostamax for prostatitis, BPH, or prostate rejuvenation. Published support is largely preclinical and regional peptide-bioregulator research.

Preclinical evidence

Rat and cellular models report reduced prostate inflammation/fibrosis and changes in chromatin/gene-regulatory pathways. Modern controlled human confirmation is lacking.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources experimental reference: 500 mcg–1 mg/day. No controlled human dosing standard exists.

Frequency

Once daily in the community protocol.

Timing

No established time-of-day requirement.

Route

Intramuscular in the community page and referenced preclinical work.

Cycle length

8–12 weeks

Reconstitution

Community reference: 2 mL bacteriostatic water per 20 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized refrigerated short-term or -20 °C long-term; reconstituted 2–8 °C and use within about 2 weeks.

Monitoring

PSA and prostate evaluation should follow normal clinical indications, not peptide marketing. Track urinary symptoms and adverse effects; CBC/CMP are general safety context.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human safety data are insufficient. Potential adverse effects include injection-site reactions, headache, fatigue, dizziness, nausea and unknown long-term effects on gene regulation, growth, metabolism or immune function.

Contraindications

No validated human contraindication profile exists. Avoid use outside research oversight in pregnancy/breastfeeding, active malignancy, significant organ disease or known hypersensitivity.

Interactions

Formal drug-interaction studies are absent or very limited. Interactions with anticancer, endocrine, metabolic and immunomodulatory therapies are unknown.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Prostamax is scientifically interesting for prostate inflammation, BPH models, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Longevity

Longevity

Cortagen

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Read guide

Longevity

Epitalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Read guide

Longevity

FOXO4-DRI

Experimental senolytic peptide research investigating selective removal of senescent cells.

Read guide